BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -25.813 Million Vs. IBES Estimate USD -30.7 Million
Reuters2026/10/26 11:01Oct 26 (Reuters) - Acumen Pharmaceuticals, Inc. Q3 operating expenses USD 25.813 million.
- Q3 net income USD -25.369 million vs. IBES estimate USD -30.3 million
- Q3 basic EPS USD -0.35
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro drifts toward the bottom of its range as US rate bets climb
Investors reportedly offering Anthropic allocation shares at premiums of up to 5% ahead of its IPO
According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.
Crypto prices
More
